335 related articles for article (PubMed ID: 30525754)
21. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study.
de Masson A; Beylot-Barry M; Ram-Wolff C; Mear JB; Dalle S; d'Incan M; Ingen-Housz-Oro S; Orvain C; Abraham J; Dereure O; Charbonnier A; Cornillon J; Longvert C; Barete S; Boulinguez S; Wierzbicka-Hainaut E; Aubin F; Rubio MT; Bernard M; Schmidt-Tanguy A; Houot R; Pham-Ledard A; Michonneau D; Brice P; Labussière-Wallet H; Bouaziz JD; Grange F; Moins-Teisserenc H; Jondeau K; Michel L; Mourah S; Battistella M; Daguindau E; Loschi M; Picard A; Franck N; Maillard N; Huynh A; Nguyen S; Marçais A; Chaby G; Ceballos P; Le Corre Y; Maury S; Bay JO; Adamski H; Bachy E; Forcade E; Socié G; Bagot M; Chevret S; Peffault de Latour R; ; ;
Lancet; 2023 Jun; 401(10392):1941-1950. PubMed ID: 37105210
[TBL] [Abstract][Full Text] [Related]
22. Management experience of advanced-stage mycosis fungoides/Sézary syndrome: a retrospective study from Spanish haematology referral units.
Novelli S; Martín A; Sánchez JJ; Espeso M; Mozos A; Briones J
Eur J Dermatol; 2020 Aug; 30(4):397-403. PubMed ID: 32815814
[TBL] [Abstract][Full Text] [Related]
23. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.
Hughes CF; Newland K; McCormack C; Lade S; Prince HM
Australas J Dermatol; 2016 Aug; 57(3):182-91. PubMed ID: 25988337
[TBL] [Abstract][Full Text] [Related]
24. How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome.
Sethi TK; Montanari F; Foss F; Reddy N
Br J Haematol; 2021 Nov; 195(3):352-364. PubMed ID: 33987825
[TBL] [Abstract][Full Text] [Related]
25. Pathogenesis and Therapy of Primary Cutaneous T-Cell Lymphoma: Collegium Internationale Allergologicum (CIA) Update 2020.
Bobrowicz M; Fassnacht C; Ignatova D; Chang YT; Dimitriou F; Guenova E
Int Arch Allergy Immunol; 2020; 181(10):733-745. PubMed ID: 32690848
[TBL] [Abstract][Full Text] [Related]
26. Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome.
Mehra T; Ikenberg K; Moos RM; Benz R; Nair G; Schanz U; Haralambieva E; Hoetzenecker W; Dummer R; French LE; Guenova E; Cozzio A
JAMA Dermatol; 2015 Jan; 151(1):73-7. PubMed ID: 25317818
[TBL] [Abstract][Full Text] [Related]
27. Allogeneic hematopoietic stem cell transplantation for heavily pretreated patients with mycosis fungoides and Sezary syndrome.
Cengiz Seval G; Sahin U; Bozdag SC; Yuksel MK; Topcuoglu P; Akay BN; Sanlı HE; Gurman G; Toprak SK; Ozcan M
Dermatol Ther; 2022 May; 35(5):e15447. PubMed ID: 35289037
[TBL] [Abstract][Full Text] [Related]
28. Are we there yet? cellular therapies for cutaneous T cell lymphoma.
Atilla PA; Atilla E
Curr Res Transl Med; 2023; 71(2):103390. PubMed ID: 37062252
[TBL] [Abstract][Full Text] [Related]
29. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
30. Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.
Berg S; Villasenor-Park J; Haun P; Kim EJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):234-243. PubMed ID: 28540671
[TBL] [Abstract][Full Text] [Related]
31. Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk-stratification, and management.
Hristov AC; Tejasvi T; Wilcox RA
Am J Hematol; 2019 Sep; 94(9):1027-1041. PubMed ID: 31313347
[TBL] [Abstract][Full Text] [Related]
32. Mycosis Fungoides and Sezary Syndrome.
Foss FM; Girardi M
Hematol Oncol Clin North Am; 2017 Apr; 31(2):297-315. PubMed ID: 28340880
[TBL] [Abstract][Full Text] [Related]
33. Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis.
Vural S; Akay BN; Botsalı A; Atilla E; Parlak N; Okçu Heper A; Şanlı H
Turk J Haematol; 2018 Mar; 35(1):35-41. PubMed ID: 28533196
[TBL] [Abstract][Full Text] [Related]
34. Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas.
Novelli S; Monter A; Pilar García-Muret M; Martino R; Briones J; Sierra J
Int J Hematol; 2019 Oct; 110(4):406-410. PubMed ID: 31317515
[TBL] [Abstract][Full Text] [Related]
35. Integrating novel systemic therapies for the treatment of mycosis fungoides and Sézary syndrome.
Prince HM; Querfeld C
Best Pract Res Clin Haematol; 2018 Sep; 31(3):322-335. PubMed ID: 30213403
[TBL] [Abstract][Full Text] [Related]
36. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.
Janiga J; Kentley J; Nabhan C; Abdulla F
Leuk Lymphoma; 2018 Mar; 59(3):562-577. PubMed ID: 29308723
[TBL] [Abstract][Full Text] [Related]
37. Mycosis fungoides and Sézary syndrome.
Jonak C; Tittes J; Brunner PM; Guenova E
J Dtsch Dermatol Ges; 2021 Sep; 19(9):1307-1334. PubMed ID: 34541796
[TBL] [Abstract][Full Text] [Related]
38. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.
Kamijo H; Miyagaki T
Curr Treat Options Oncol; 2021 Jan; 22(2):10. PubMed ID: 33415447
[TBL] [Abstract][Full Text] [Related]
39. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas.
Isufi I; Seropian S; Gowda L; Wilson LD; Roberts K; Girardi M; Perreault S; Foss F
Leuk Lymphoma; 2020 Dec; 61(12):2955-2961. PubMed ID: 32643494
[TBL] [Abstract][Full Text] [Related]
40. What factors guide treatment selection in mycosis fungoides and Sezary syndrome?
Kim YH
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):303-312. PubMed ID: 34889422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
